drugset / Trial / NCT05360602

Alpha Lipoic Acid Effect on No-Reflow Phenomenon

NCT05360602

Completed 70 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelPrevention

Summary

Prospective, randomized, open-label, controlled clinical trial to evaluate the efficacy and tolerability of Alpha Lipoic Acid administration on oxidative stress, inflammatory markers, clinical outcome and occurrence of No-Reflow in post myocardial infarction (MI) patients by assessment of aldehyde dehydrogenase-2 (ALDH2) as a marker of oxidative stress and paraoxonase-1 (PON-1) as a marker of oxidative stress and inflammation.

Timeline

Start
2022-01-01
Primary completion
2023-07-01
Completion
2024-01-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject alpha-lipoic acid Small molecule 600 mg Intravenous

Indications

No indication recorded.